Sepax-2 cell processing device: a study assessing reproducibility of concentrating thawed hematopoietic progenitor cells.

ABSTRACT:

Background

Autologous hematopoietic progenitor cell (HPC) transplantation is currently the standard of care for a fraction of patients with newly diagnosed myelomas and relapsed or refractory lymphomas. After high-dose chemotherapy, cryopreserved HPC are either infused directly after bedside thawing or washed and concentrated before infusion. We previously reported on the comparability of washing/concentrating HPC post-thaw vs. infusion without manipulation in terms of hematopoietic engraftment, yet settled for the prior favoring cell debris and DMSO removal. For almost two decades, automation of this critical step of washing/concentrating cells has been feasible. As part of continuous process verification, we aim to evaluate reproducibility of this procedure by assessing intra-bat

SUBMITTER: Mfarrej B 

PROVIDER: S-EPMC9632571 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature